CompanyGraph
Designs classified nuclear facilities for the U.S. government using engineers who already hold the security clearances required to legally do the work.
- Most companies in its industry are production businesses; this one is a sense-making business
- Depends onUpstream position: supplies 5 industries, depends on 0
- ScaleMarket cap is above the global median
- FinancialsAltman Z-Score: safe zone
- Interpretations3 currently firing — 1 · 2
Latest report · July 7, 2026
Read the full structural reportWhat this company is and how it runs — written from structure, not news.
- Most companies in its industry are production businesses; this one is a sense-making business
Jacobs Solutions runs engineering programs for the Department of Energy and Department of Defense where the work itself is classified — meaning only engineers who already hold Q-level or TS/SCI clearances can legally enter the facilities and touch the designs. Getting a new engineer cleared takes 12 to 18 months of federal background investigation, so if a federal program office tried to swap Jacobs out mid-program, every specialized role would go unstaffed for over a year while replacements went through adjudication, which active nuclear modernization programs cannot absorb. The same contamination-control discipline those cleared engineers use to design classified nuclear facilities also qualifies them to validate sterile manufacturing environments for pharmaceutical clients, so the same bench of people generates revenue from both federal milestone payments and pharmaceutical commissioning contracts. The whole structure depends on keeping that bench intact — if enough senior cleared engineers retire or are poached before replacements can be badged, Jacobs cannot staff the classified contracts it is already under obligation to deliver.
How does this company make money?
Federal clients — primarily DOE and DOD — pay through cost-plus-fixed-fee contracts, meaning the company is reimbursed for its costs and earns a fixed fee on top, with payments released as specific program milestones are met. Pharmaceutical clients pay a fixed lump-sum price for facility construction and commissioning, with progress payments tied to hitting commissioning milestones. The company also earns hourly consulting fees for advisory work.
What makes this company hard to replace?
A federal program office that wanted to replace this company would have to wait 12 to 18 months for a new integrator's staff to be cleared and badged before classified work could resume — a delay that active DOE and DOD programs cannot absorb. The company also holds established working relationships with the federal contracting officers and COTRs managing its multi-year IDIQ vehicles, which take years to build. On the pharmaceutical side, the company's facility designs and validation protocols are already written into clients' FDA regulatory filings; changing those protocols requires extensive requalification, which is expensive and time-consuming.
What limits this company?
Getting a Q-level or TS/SCI clearance takes 12 to 18 months of federal background investigation — there is no shortcut, no matter how much money is available for recruiting. Every time a cleared engineer leaves, that role sits empty for up to 18 months before a replacement can legally enter a classified facility. That replenishment lag is the hard ceiling on how fast the company can grow or recover from attrition.
What does this company depend on?
The company cannot operate without the active Q-level and TS/SCI clearances held by its own engineering staff — those clearances are investigated and held by individuals, not by the company as an entity. It also depends on FDA and EMA regulatory expertise for pharmaceutical facility validation, access to IDIQ contract vehicles with federal agencies, specialized clean room design software and commissioning protocols, and bonding capacity large enough to cover major infrastructure projects.
Who depends on this company?
The U.S. Department of Energy relies on this company to keep nuclear weapons facility modernization programs moving — if those projects stalled, the broader nuclear weapons complex would face program delays it cannot easily route around. Biopharmaceutical manufacturers depend on the company's sterile manufacturing facility work; if a facility failed to pass commissioning, drug production at that plant would be bottlenecked. Municipal water utilities that have projects under construction would lose treatment capacity if those projects were abandoned mid-build.
How does this company scale?
Program management methods and digital project management platforms can be spread across many concurrent projects without much added cost — that part scales well. What does not scale quickly is cleared headcount: clearance processing takes 12 to 18 months, and nuclear facility engineering expertise takes years of hands-on experience to build. Every new classified program the company wins must be staffed from the bench it already has.
What external forces can significantly affect this company?
Federal budget appropriation cycles and continuing resolutions can freeze or delay funding for multi-year defense and DOE programs even when contracts are already in place. If the FDA changes its sterile manufacturing requirements mid-project, pharmaceutical facilities under construction may need to be redesigned at significant cost. Shifts in geopolitical tensions can change the priority or scope of classified nuclear modernization programs, directly affecting how much work flows through those contract vehicles.
Where is this company structurally vulnerable?
If a competitor aggressively recruited the company's senior cleared nuclear engineers, or if a wave of retirements hit that cohort at once, the company would face a staffing gap of 12 to 18 months on programs that are already running. Because DOE milestone payments are tied to work that only cleared engineers can perform, those delays would quickly make the existing contracts impossible to fulfill — and the federal program offices cannot simply wait 18 months for replacements to be badged.
Price is read as structure — trend, levels, range, peak and volatility drawn on the chart. It does not predict where price goes next.
Sign in to view price data.
Sign in1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow is this stock behaving?
Close In Upper Portion Of Recent Range, Bollinger Bands, And RSI
Current close sits in the upper portion of the 14-week high-low range; current close sits in the upper portion of its 20-week Bollinger Bands; RSI sits above its 20-week recent mean (Bollinger %B applied to RSI).
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
What the company actually pays, and whether its own cash supports it.
The reported statements, read against the company's own industry.
2 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Goodwill-Heavy Equity
Equity position looks solid, but the composition deserves a look. Equity ratio is elevated for its industry while goodwill is a large share of total assets and large relative to shareholders equity. The equity cushion sits substantially on acquisition-premium book value rather than on retained earnings or paid-in capital.
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Three multi-year observations co-occur: revenue increased year-over-year in each of the last three fiscal years, gross profit (absolute level) increased year-over-year in each of the last four fiscal years, and net income was positive in each of the last five fiscal years. The configuration describes growth-and-profitability persistence across three different windows.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Financial Health
Supply Chain
Scale
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.
Latest Jacobs Solutions report
Jacobs Solutions Inc.
July 7, 2026 · CompanyGraph · J
Jacobs Solutions posted positive net income in every fiscal year from FY2021 through FY2025 (latest statement September 2025, confirmed by recomputing its reported figures), with revenue and gross profit both rising in recent years and dividends covered by free cash flow. What stood out: unlike most engineering-and-construction firms, CompanyGraph reads this one not as a builder of things but as an expertise-led firm whose real ceiling may be how fast scarce, highly specialized engineers can be replenished — a reading, not a fact, and one the data on file can't yet test.
Read the full report